Grail, a US-Hong Kong Diagnostics Company, May Stage $500 Million Hong Kong IPO
publication date: Mar 1, 2018
Grail, a US spinout from Illumina that is developing blood-based cancer detection tests, is considering a $500 million Hong Kong IPO. Last year, Grail completed a $900 million Series B fundraising, the largest ever. In June, Grail merged with Cirina, a Hong Kong cancer diagnostics company, which was co-founded by Dennis Lo, DM, DPhil, an early scientific leader in the field of molecular diagnostics. Grail is considering Hong Kong for its IPO venue following new HKEX rules that allow companies to IPO even if they aren't profitable and to offer two classes of stock, one with voting rights (for the original owners) and one without. More details....
Stock Symbol: (NSDQ: ILMN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.